Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease. Revised Protocol 10 incorporating Protocol Amendment 16 + Pharmacogenetics Blood Sample Amendment 01 - Site Specific (v2.0, dated 03-Mar-2009)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Avagacestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 28 Sep 2015 Results published in the JAMA Neurology.
- 14 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
- 14 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .